Literature DB >> 9261261

Modulation of tissue factor protein expression in experimental venous bypass grafts.

K M Channon1, G J Fulton, M G Davies, K G Peters, M D Ezekowitz, P O Hagen, B H Annex.   

Abstract

Vein graft failure is a major limitation of coronary artery and peripheral vascular surgery. Tissue factor (TF), a transmembrane glycoprotein, generates thrombin by initiating the extrinsic coagulation cascade and plays a major role in the response to arterial injury. This study was designed to examine changes in TF protein expression in response to venous bypass grafting. New Zealand White rabbits underwent interposition bypass grafting of the common carotid artery via the ipsilateral external jugular vein. The contralateral control jugular veins (n = 6), early vein grafts (1 or 3 days after grafting, n = 18), and late vein grafts (14 or 28 days after grafting, n = 8) were examined by immunohistochemistry. The presence or absence of TF immunostaining in the intima was assessed in each vessel quadrant. In control veins, intimal TF staining was present in 5 of 24 vessel quadrants. In early vein grafts, TF staining was markedly increased in the intima (72 of 72 quadrants, P < .001 vs control veins), and TF immunostaining colocalized with CD18-positive leukocytes but not with endothelial cells, vascular smooth muscle cells, or RAM11-positive macrophages. In late vein grafts with intimal hyperplasia, TF expression was low or absent in the intima (6 of 32 quadrants, P < .001 vs early vein grafts; P = NS vs control veins), although medial smooth muscle cells expressed TF. Marked changes in TF expression occur in vein grafts. In early vein grafts, TF protein was greatly increased in the intima for at least 3 days and was associated with CD18-positive leukocytes. In late vein grafts with intimal hyperplasia, however, TF protein was not seen in the intima. These findings may have important implications for the development of therapeutic strategies to limit vein graft failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261261     DOI: 10.1161/01.atv.17.7.1313

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

Review 1.  Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology.

Authors:  S Saskena; M J Domanski; E J Benjamin; A J Camm; M D Ezekowitz; B J Gersh; J Jalife; G V Naccarelli; R E Vlietstra; D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

Review 2.  Antithrombotic strategies in gene therapy.

Authors:  K M Channon; B H Annex
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

3.  CD40 ligation induces tissue factor expression in human vascular smooth muscle cells.

Authors:  U Schönbeck; F Mach; G K Sukhova; M Herman; P Graber; M R Kehry; P Libby
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts.

Authors:  Navin K Kapur; Ce Bian; Edward Lin; Clayton B Deming; Jason L Sperry; Baranda S Hansen; Nikolaos Kakouros; Jeffrey J Rade
Journal:  J Vasc Surg       Date:  2011-07-31       Impact factor: 4.268

5.  Early adaptive responses of the vascular wall during venous arterialization in mice.

Authors:  Stephanie Kwei; George Stavrakis; Masaya Takahas; George Taylor; M Judah Folkman; Michael A Gimbrone; Guillermo García-Cardeña
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 6.  Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery.

Authors:  Alistair J Geraghty; Karen Welch
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.